Payment overview · 2025
General Payments
$117.31
6 reported records · 6 companies
Healthcare provider profile · identity verified
Mandy A Klass, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · GLANDORF, OH · NPI 1235135260
Verified facts
What the public records show
CMS Open Payments records show Mandy A Klass, M.D. received $117.31 in general payments during 2025 across 6 reported records.
Exact Sciences Corporation accounted for 20.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 128 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 121 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $23.45 | 20.0% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $22.27 | 19.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $19.07 | 16.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.86 | 16.1% | 1 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $17.66 | 15.1% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $16.00 | 13.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $117.31 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $23.45 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $22.27 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $19.07 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.86 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.86 | 1 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $17.66 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $16.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 128 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
50 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
52 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
128 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
121 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1049 | 255 |
| Levothyroxine Sodium | Levothyroxine Sodium | 691 | 150 |
| Metoprolol Succinate | Metoprolol Succinate | 567 | 151 |
| Losartan Potassium | Losartan Potassium | 522 | 120 |
| Amlodipine Besylate | Amlodipine Besylate | 482 | 120 |
| Omeprazole | Omeprazole | 450 | 119 |
| Metformin Hcl | Metformin Hcl | 445 | 94 |
| Pantoprazole Sodium | Pantoprazole Sodium | 387 | 88 |
| Hydrochlorothiazide | Hydrochlorothiazide | 384 | 87 |
| Lisinopril | Lisinopril | 347 | 75 |
| Sertraline Hcl | Sertraline Hcl | 336 | 78 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 327 | 86 |
| Metoprolol Tartrate | Metoprolol Tartrate | 294 | 61 |
| Furosemide | Furosemide | 285 | 60 |
| Simvastatin | Simvastatin | 283 | 85 |
| Potassium Chloride | Potassium Chloride | 265 | 67 |
| Eliquis | Apixaban | 232 | 49 |
| Gabapentin | Gabapentin | 229 | 46 |
| Donepezil Hcl | Donepezil Hcl | 221 | 44 |
| Montelukast Sodium | Montelukast Sodium | 204 | 50 |
| Fluticasone Propionate | Fluticasone Propionate | 202 | 82 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 179 | 52 |
| Clopidogrel | Clopidogrel Bisulfate | 156 | 39 |
| Duloxetine Hcl | Duloxetine Hcl | 153 | 35 |
| Fenofibrate | Fenofibrate | 152 | 45 |
| Bupropion Xl | Bupropion Hcl | 151 | 36 |
| Meloxicam | Meloxicam | 150 | 42 |
| Citalopram Hbr | Citalopram Hydrobromide | 142 | 37 |
| Tamsulosin Hcl | Tamsulosin Hcl | 141 | 42 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 135 | 30 |
| Mounjaro | Tirzepatide | 128 | 23 |
| Glimepiride | Glimepiride | 126 | 33 |
| Prednisone | Prednisone | 123 | 80 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 123 | 30 |
| Trulicity | Dulaglutide | 121 | 21 |
| Metformin Hcl Er | Metformin Hcl | 120 | 35 |
| Fluoxetine Hcl | Fluoxetine Hcl | 108 | 24 |
| Carvedilol | Carvedilol | 107 | 20 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 107 | 20 |
| Buspirone Hcl | Buspirone Hcl | 105 | 19 |
| Trazodone Hcl | Trazodone Hcl | 105 | 27 |
| Famotidine | Famotidine | 99 | 20 |
| Allopurinol | Allopurinol | 95 | 27 |
| Tramadol Hcl | Tramadol Hcl | 94 | 20 |
| Warfarin Sodium | Warfarin Sodium | 94 | 17 |
| Levetiracetam | Levetiracetam | 92 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 91 | 16 |
| Alendronate Sodium | Alendronate Sodium | 90 | 26 |
| Memantine Hcl | Memantine Hcl | 90 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 90 | 21 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 88 | suppressed |
| Methylprednisolone | Methylprednisolone | 83 | 75 |
| Ondansetron Odt | Ondansetron | 83 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 82 | 35 |
| Alprazolam | Alprazolam | 82 | 27 |
| Ezetimibe | Ezetimibe | 81 | 23 |
| Bumetanide | Bumetanide | 78 | 20 |
| Fenofibrate | Fenofibrate Nanocrystallized | 77 | 20 |
| Sucralfate | Sucralfate | 76 | 15 |
| Xarelto | Rivaroxaban | 75 | 17 |
| Januvia | Sitagliptin Phosphate | 68 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 67 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 67 | 15 |
| Finasteride | Finasteride | 66 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 65 | 32 |
| Synthroid | Levothyroxine Sodium | 63 | 18 |
| Loperamide | Loperamide Hcl | 61 | 20 |
| Repatha Sureclick | Evolocumab | 61 | 15 |
| Cephalexin | Cephalexin | 60 | 48 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 58 | 13 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 55 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 54 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 53 | 12 |
| Jardiance | Empagliflozin | 52 | 12 |
| Atenolol | Atenolol | 51 | 12 |
| Ozempic | Semaglutide | 51 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 50 | 43 |
| Farxiga | Dapagliflozin Propanediol | 50 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 50 | 31 |
| Enalapril Maleate | Enalapril Maleate | 48 | suppressed |
| Mirtazapine | Mirtazapine | 46 | suppressed |
| Azithromycin | Azithromycin | 43 | 38 |
| Myrbetriq | Mirabegron | 43 | suppressed |
| Tradjenta | Linagliptin | 42 | suppressed |
| Topiramate | Topiramate | 41 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 40 | 15 |
| Spironolactone | Spironolactone | 40 | 14 |
| Memantine Hcl Er | Memantine Hcl | 39 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 39 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 39 | suppressed |
| Cefdinir | Cefdinir | 38 | 35 |
| Flecainide Acetate | Flecainide Acetate | 37 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 36 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 36 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 36 | suppressed |
| Primidone | Primidone | 35 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 34 | 18 |
| Fluconazole | Fluconazole | 34 | 17 |
| Lorazepam | Lorazepam | 34 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 34 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 33 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 33 | 30 |
| Irbesartan | Irbesartan | 33 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 33 | suppressed |
| Nitroglycerin | Nitroglycerin | 33 | 18 |
| Latanoprost | Latanoprost | 32 | suppressed |
| Rybelsus | Semaglutide | 32 | suppressed |
| Baclofen | Baclofen | 31 | suppressed |
| Celecoxib | Celecoxib | 31 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 31 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 31 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 30 | suppressed |
| Lovastatin | Lovastatin | 30 | suppressed |
| Telmisartan | Telmisartan | 30 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 30 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 29 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 28 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 28 | suppressed |
| Ibuprofen | Ibuprofen | 27 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 26 | suppressed |
| Pregabalin | Pregabalin | 26 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 25 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 25 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 24 | 12 |
| Fenofibric Acid | Fenofibric Acid (Choline) | 24 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 24 | 24 |
| Rivastigmine | Rivastigmine | 24 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 23 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 23 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 23 | suppressed |
| Metolazone | Metolazone | 23 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 23 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 23 | suppressed |
| Clozapine | Clozapine | 22 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 22 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 22 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 21 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 18 |
| Nystatin | Nystatin | 21 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Ramipril | Ramipril | 20 | suppressed |
| Risperidone | Risperidone | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 19 |
| Fenofibrate | Fenofibrate,micronized | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | 12 |
| Methenamine Hippurate | Methenamine Hippurate | 19 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Valsartan | Valsartan | 19 | suppressed |
| Verapamil Sr | Verapamil Hcl | 19 | suppressed |
| Anastrozole | Anastrozole | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Digoxin | Digoxin | 18 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 17 | 16 |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Klor-Con M20 | Potassium Chloride | 17 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 16 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 16 | suppressed |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 16 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 16 | suppressed |
| Brilinta | Ticagrelor | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 15 | suppressed |
| Gemfibrozil | Gemfibrozil | 15 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | 13 |
| Naproxen | Naproxen | 14 | suppressed |
| Olanzapine | Olanzapine | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Restasis | Cyclosporine | 14 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 13 | suppressed |
| Letrozole | Letrozole | 13 | suppressed |
| Mirabegron Er | Mirabegron | 13 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Budesonide | Budesonide | 12 | suppressed |
| Cyclosporine | Cyclosporine | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Insulin Aspart | Insulin Aspart | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Trospium Chloride | Trospium Chloride | 12 | suppressed |
| Calcitriol | Calcitriol | 11 | suppressed |
| Clonazepam | Clonazepam | 11 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Dulera | Mometasone/Formoterol | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | 11 |
| Novolog | Insulin Aspart | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $117.31 · 6 records | Exact Sciences Corporation | BREZTRI, Dexcom G6 Transmitter, FREESTYLE LIBRE 3, MOUNJARO, REZDIFFRA, The Cologuard Plus Collection Kit, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error